Intriguing new ulcerative colitis treatment

The usual suspects...

Very earlier today, a follower sent me a remarkable piece of news. But first a little bit of recent history, in line with my prior substack on Pfizer, superantigens, and AI. Pfizer bragged for months that its supply chain and logistics were so good it would be able to trace every single vaccine to each arm it was injected. Why is this important ?

Because of data. With proper data, you can either use advanced algorithms or train your AI models to both find patterns and “predict” (I much prefer the word forecast) the rise in diseases, especially if one of your datasets is social media information. After months of forecasting diseases after the initial “reverse engineering” of the mRNA molecular pathways, I and this gifted friend independently saw the same trend. Me, him, and other researchers found a possible disease-inducing pathway, and weeks later one of the big pharmaceutical companies acquired a biotech startup dealing with the precise molecule or rare disease.

While I stand by this assertion, regardless of how the big pharmaceutical companies decided to acquire intriguing biotech startups, the fact remains they are able to forecast possible future trends, and hedged their bet accordingly.

Source

Biotech firm Roivant Sciences (ROIV.O) on Thursday launched a company with Pfizer Inc (PFE.N) focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market.

The drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest.

The deal hands over the development of the drug to the new company, along with commercial rights to the treatment in the United States and Japan for no upfront payment. Pfizer will hold commercial rights outside of the two countries.

Why this monoclonal antibody got enough of my attention ? RVT-3101 is a monoclonal antibody against a specific protein the TL1A (Tumor necrosis factor-like cytokine 1A). It plays an important role in regulating the immune system, particularly in our interests, T cell function, and differentiation.

It can influence the production of cytokines by T-Cells, and it can also enhance the production of certain pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17). It has a potent effect on promoting naive CD4+ (new CD4 cells) into Th17 cells, which increases the production of IL-17. By blocking this protein and its interaction with its own receptor DR3 (Death Receptor 3… kind of a cool name) it can positively modulate inflammatory diseases, potentially stopping autoimmune diseases from progressing since many autoimmune diseases are “fueled” by Th17 cells and the inflammatory loop it creates. Under specific conditions Th17 T cells and IL-17(A) can fuel neurodegeneration too, its role in cancer progression or protection is highly debated, as anything to do with cancer (one of, if not the most contradictory pathology in modern science).

Monoclonals are a very expensive treatment for life. And they are often followed by nasty side effects.

Older substack article

Modulating Th17 immune responses is especially dangerous because it plays a protective role in certain infections but especially significant and potent against extracellular bacteria and fungi. The hallmark of treatment with monoclonals, as you can see in the image, is both. Yet if proven to be actually effective, come hell or high water they will make tens of billions in profit over the next 10 to 15 years. As I wrote merely a few days ago, Th17 responses are at the core of many of the pathologies onset by the mRNA vaccine, either the initial onset, the middle of the road, or “turbo” diseases.

Being aware of some of Pfizer’s partnerships and acquisitions can lead to different levels of insight, and you can deduce based on observation how much “they knew”, and I believe on this specific issue of mRNA-dominant Th17, they knew, they were fully aware. Depressingly enough, millions will be hostage to these expensive, patented, exclusive treatments, so every once in a while I try to raise awareness.


And If you are asking yourself if there are other ways, yes, you can modulate or ameliorate many conditions where this specific immune response is damaging in different ways here are some of the things you can use:

• NAC

• Vitamin D

• Metformin or Berberine

• Fisetin

• Thiamine (Vitamin B1)

• Niacin (somewhat indirectly)

• Nicotinamide Riboside (directly)
  
  Repetitive for obvious reasons, since primarily I built our “hypothesis” on the Th17 pathway and mechanism and slowly but surely expanded from it, to where we are now. As a last addendum if you or someone you know suffer from a severe case of UC, a better course of action would be addition some of these supplements, and a dietary change (it sounds counterproductive but often people with UC eat too much fiber), and perhaps considering using BPC-157, one of the most common peptides used to treat inflammatory conditions, especially in the gut.
  

A trivia for your consideration, and I don’t possess the answer, yet. Why many monoclonal antibodies are created using parts of IgG4 ? Curious I would say.

Source

Source

On a tangential note, imagine being such a psychopath you write this.

Should Your Kids Get the New RSV Monoclonal Antibody?

A new FDA-approved monoclonal antibody may help block a virus that overwhelmed children’s hospitals last year.

The following video is the definition of the next decade. The very definition of our times.

Thank you if you chose to support my work and thank you for reading.